Xenon Pharmaceuticals Inc.
XENE
$55.23
-$2.67-4.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.80% | -7.31% | -30.22% | 0.97% | -4.61% |
| Total Depreciation and Amortization | -4.68% | 1.42% | -4.10% | -1.05% | -0.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.88% | -21.36% | 15.32% | 97.91% | -44.86% |
| Change in Net Operating Assets | 80.70% | 89.21% | 121.51% | -494.63% | 352.45% |
| Cash from Operations | -13.56% | -11.71% | -4.19% | -13.36% | -9.50% |
| Capital Expenditure | -13.17% | -78.98% | -265.12% | 94.51% | -32.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 62.36% | -52.91% | 138.52% | -65.20% | 9,025.55% |
| Cash from Investing | 62.72% | -53.16% | 138.37% | -64.97% | 19,679.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,710.89% | 3,530.77% | -94.35% | -90.51% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,710.89% | 3,530.77% | -94.35% | -90.51% | -- |
| Foreign Exchange rate Adjustments | -1,633.33% | -100.95% | 1,087.50% | 94.47% | -2,242.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 406.63% | -264.85% | 171.86% | -147.29% | 212.17% |